RELATION BETWEEN REGULATORY T CELLS, CA-125 LEVEL AND TUMOR MASS IN OVARIAN CANCER PATIENTS
https://doi.org/10.15789/1563-0625-2010-4-5-311-318
Abstract
The relationship between various subpopulations of regulatory T-cells (Treg) and serum level of CA-125 and dynamics of Treg following surgery in ovarian cancer (OC) patients have been investigated. The typical for OC peripheral blood Treg changes (the enchantment of CD4+FoxP3+ и CD8+FoxP3+ T-cells and decrease of CD4+CD25+/CD4+CD25high Т-cells due to their migration to ascites) have been revealed only in patients with elevated CA-125 level and were not registered in patient's group with normal level of this antigen. CA-125 serum level was directly correlated to absolute count of CD4+CD25high Т-cells and was in reverse relation to CD8+FoxP3+ T-cells. Surgical removal of a tumor was accompanied by remarkable reduction of CA-125 level in all cases. However Treg changes were observed only in patients with optimal cytoreductive surgery and were evidenced by CD4+CD25+/CD4+CD25high Т-cell normalization, whereas the number of these cells in peripheral blood of patients with residual tumors after surgery remained decreased. At that percentage of CD4+FoxP3+ и CD8+FoxP3+ Т-cells 2 weeks after surgery was unchanged and their increased number was associated with persisted decrease of T-cell proliferation in response to anti-CD3 stimulation.
About the Authors
E. R. Chernykh
НИИ клинической иммунологии СО РАМН, г. Новосибирск
Russian Federation
Russian Federation
E. V. Kurganova
НИИ клинической иммунологии СО РАМН, г. Новосибирск
Russian Federation
Russian Federation
M. A. Tikhonova
НИИ клинической иммунологии СО РАМН, г. Новосибирск
Russian Federation
Russian Federation
E. G. Laskavaya
Городская муниципальная клиническая больница № 1, г. Новосибирск
Russian Federation
Russian Federation
V. A. Lebedeva
Городская муниципальная клиническая больница № 1, г. Новосибирск
Russian Federation
Russian Federation
A. A. Ostanin
НИИ клинической иммунологии СО РАМН, г. Новосибирск
Russian Federation
Russian Federation
References
1. Курганова Е.В., Тихонова М.А., Коваленко В.Ф., Лебедева В.А., Ласкавая Е.Г., Останин А.А., Черных Е.Р. Характеристика регуляторных Т-клеток у больных раком яичника//Сибирский онкологический журнал. -2008. -№ 6 (30). -С. 40-45.
2. Курганова Е.В., Тихонова М.А., Ласкавая Е.Г., Лебедева В.А., Звездина Н.Ю., Безбородова В.И., Гончаров М.А., Лебедева В.А., Останин А.А., Черных Е.Р. Регуляторные Т-клетки при доброкачественных и злокачественных опухолях яичников//Иммунология. -2009. -№ 6. -С. 349-355.
3. Сергеева Н.С., Ермошина Н.В., Мишунина М.П. Использование опухолеассоциированных маркёров для диагностики и контроля за эффективностью терапии у больных с распространенным раком яичников//М.: МНИОИ им. П.А. Герцена, 2002.
4. Allan S.E., Crome S.Q., Crellin N.K., Passerini L., Steiner T.S., Bacchetta R., Roncarolo M.G., Levings M.K. Activation-induced FoxP3 in human T effector cells does not suppress proliferation or cytokine production//Intern. Immunol. -2007. -Vol. 19. -P. 345-354.
5. Bast R.S., Feeney M., Lazarus H., Nadler L.M., Colvin R.B., Knapp R.C. Reactivity of a monoclonal antibody with human ovarian carcinoma//J. Clin. Invest.-1981. -Vol. 68. -P. 1331-1337.
6. Beyer M., Schultze J.L. Regulatory T cells in cancer//Blood. -2006. -Vol. 108, № 3. -P. 804-811.
7. Bonelli M., Savitskaya A., Steiner C.-W., Rath E., Smolen J.S., Scheinecker C. Phenotypic and functional analysis of CD4+CD25-Foxp3+ T cells in patients with systemic lupus erythematosus//J. Immunol. -2009. -Vol. 182. -P. 1689-1695.
8. Canney P.A., Moore M., Wilkinson P.M., James R.D. Ovarian cancer antigen CA-125: a prospective clinical assessment of its role of a tumor marker//Br. J. Cancer. -1984. -Vol. 50, N 6. -P. 765-769.
9. Chaput N., Louafi S., Bardier A., Charlotte F., Vaillant J-C., Menegaux F., Rosenzwajg M., Lemoine F., Klatzmann D., Taieb J. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue//Gut. -2009. -Vol. 58, N 4. -P. 520-529.
10. Chattopadhyay S., Chakraborty N.G., Mukherji B. Regulatory T cells and tumor immunity//Can. Immunol. Immunother. -2005. -Vol. 54. -P. 1153 -1161.
11. Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., McGrady G., Wahl S.M. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor FoxP3//J. Exp. Med. -2003. -Vol. 198. -P. 1875-1886.
12. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M.L., Knutson K.L., Chen L., Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival//Nat. Med. -2004. -Vol. 10, N 9. -P. 942-949.
13. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells//Nat. Immunol. -2003. -Vol. 4. -P. 330-336.
14. Gadducci A., Cosio S., Tana R., Genazzani A.R. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer//Crit. Rev. Oncol. Hematol. -2009. -Vol. 69, N 1. -P. 12-27.
15. Gonzalez H.D., Figueras J. Effect of surgical resection of metastatic disease on immune tolerance to cancer. How a systemic disease could be controlled by a local therapy//Clin. Transl. Oncol. -2007. -Vol. 9. -P. 571-577.
16. Gupta D., Lis C.G. Role of CA-125 in predicting ovarian cancer survival -a review of the epidemiological literature//J. Ovarian. Res. -2009. -Vol. 2: 13 (BioMed Central http://www.ovarianresearch.com/content/2/1/13).
17. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3//Science. -2003. -Vol. 299. -P. 1057-1061.
18. Jonuleit H., Schmitt E. The regulatory T cell family: distinct subsets and their interrelations.//J. Immunol. -2003. -Vol. 171. -P. 6323-6327.
19. Kono K., Kawaida H., Takahashi A., Sugai H., Mimura K., Miyagawa N., Omata H., Fujii H. CD4+CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers // Cancer Immunol. Immunother. - 2006. - Vol. 55, N. 9. - P. 1064-1071.
20. Münstedt K., Krisch M., Sachsse S., Vahrson H. Serum CA-125 levels and survival in advanced ovarian cancer // Arch. Gynecol. Obstet. - 1997. - Vol. 259. - P. 117-123
21. Shafer-Weaver K.A, Anderson M.J., Stagliano R., Malyguine A., Greenberg N.M., Hurwitz A.A Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells//J. Immunol. -2009. -Vol. 183, N 8. -P. 4848-4852.
22. Shimizu J., Yamazaki S., Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells a common basis between tumor immunity and autoimmunity//J. Immunol. -1999. -Vol. 163. -P. 5211-5218.
23. Tokuno K., Hazama S., Yoshino S., Yoshida S., Oka M. Increased prevalence of regulatory T-cells in the peripheral blood of patients with gastrointestinal cancer//Anticancer Res. -2009. -Vol. 29, N 5. -P. 1527-1532.
24. Walker M. R., Carson B.D., Nepom G.T., Ziegler S.F., Buckner J.H. De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25-cells//Proc. Natl. Acad. Sci. USA. -2005. -Vol. 102. -P. 4103-4108.
25. Wei S., Kryczek I., Zou W. Regulatory T-cells compartmentalization and trafficking//Blood. -2006. -Vol. 108. -P. 426-431.
26. Zhou G., Levitsky H.I. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance//J. Immunol. -2007.-Vol. 178. -P. 2155-2162.
27. Zou W. Regulatory T cells, tumor immunity and immunotherapy//Nat. Rev. Immunol. -2006. -Vol. 6. -P. 295-307.
Review
For citations:
Chernykh E.R., Kurganova E.V., Tikhonova M.A., Laskavaya E.G., Lebedeva V.A., Ostanin A.A. RELATION BETWEEN REGULATORY T CELLS, CA-125 LEVEL AND TUMOR MASS IN OVARIAN CANCER PATIENTS. Medical Immunology (Russia). 2010;12(4-5):311-318. (In Russ.) https://doi.org/10.15789/1563-0625-2010-4-5-311-318
Views:
814
Email this article 